UNSPSC 51372117: Dihydrocodeine bitartrate

This classification denotes an opioid receptor agonist and opioid with the molecular formula C18H23NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8LXS95BSA9, chemically known as 7, 8-dihydrocodeine but more generally known as dihydrocodeine bitartrate, which bears US NIH Compound Identifier 3063. European Medicines Agency schedules Dihydrocodeine bitartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01704MIG.

UNSPSC 51372117 Dihydrocodeine bitartrate is a Commodity code that nominally identifies a specific opioid pharmaceutical product, but recent state and local solicitation activity under this code shows a material mismatch with the code's stated scope. Seminole County, Florida issued an IFB in June 2026 for naloxone and safe drug deactivation systems — harm-reduction and overdose-reversal products fundamentally distinct from dihydrocodeine bitartrate, a controlled opioid medication used for pain management and cough suppression. The procurement request itself indicates the code has been applied to a broader harm-reduction and public health initiative rather than pharmaceutical inventory management for dihydrocodeine itself. State and local issuing bodies using this code appear limited to health departments and county-level community health agencies focused on opioid response programming.

Seminole County's IFB 60459723LAS, due July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract runs two years with a one-year renewal option, includes drug-free workplace and E-Verify compliance requirements, and carries a three-month probationary termination clause. Potential FEMA funding introduces federal compliance obligations including the Clean Air Act and Federal Water Pollution Control Act. The code shows limited recent activity and, given the divergence between the Commodity's pharmaceutical classification and the actual procurement scope, may indicate either miscoding within the issuing jurisdiction or a broader state and local trend toward using pharmaceutical taxonomy codes for public health supply acquisitions that fall outside traditional drug-inventory categories. Geographic spread from available records is limited to Florida.